Skip to main content
Terug
Watch Compare

BioNexus Gene Lab Corp

Datakwaliteit: 100%
BGLC
NASDAQ Services Health Services
€ 2,18
▼ € 0,07 (-3,08%)
Marktkapitalisatie: 5,32 M
Prijs
€ 2,25
Marktkapitalisatie
5,32 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -4,41% annually over 5 years
Negative free cash flow of -2,91 M
Capital efficient — spends only 0,42% of revenue on capex

Groei

Revenue Growth (5Y)
-4,41%
Onder sectorgemiddelde (3,76%)
Revenue (1Y)-2,66%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-32,04%
Onder sectorgemiddelde (-15,99%)
ROIC-25,40%
Net Margin-24,27%
Op. Margin-24,81%

Veiligheid

Debt / Equity
N/A
Current Ratio8,30
Interest CoverageN/A

Waardering

PE (TTM)
-2,31
Onder sectorgemiddelde (-1,17)
P/B Ratio0,78
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Services sector mediaan (515 peers)
Metriek Aandeel Sector Mediaan
P/E -2,3 -1,2
P/B 0,8 1,4
ROE % -32,0 -16,0
Net Margin % -24,3 -19,4
Rev Growth 5Y % -4,4 3,8
D/E — 0,4

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

All Fundamental Metrics
Growth
Revenue Growth (1Y) -2,66% Revenue Growth (3Y) -6,71%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -4,41% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9,47 M Net Income (TTM) -2,30 M
ROE -32,04% ROA -26,95%
Gross Margin 14,77% Operating Margin -24,81%
Net Margin -24,27% Free Cash Flow (TTM) -2,91 M
ROIC -25,40% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,30
Interest Coverage N/A Asset Turnover 1,11
Working Capital 4,95 M Tangible Book Value 6,82 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,31 Forward P/E N/A
P/B Ratio 0,78 P/S Ratio 0,56
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -54,72%
Market Cap 5,32 M Enterprise Value 5,32 M
Per Share
EPS (Diluted TTM) -1,18 Revenue / Share 4,00
FCF / Share -1,23 OCF / Share -1,21
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,42% FCF Conversion 126,66%
SBC-Adj. FCF -3,05 M Growth Momentum 1,75

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2021
Revenue 9,51 M 9,77 M 10,93 M 11,39 M 13,36 M
Net Income -1,60 M -2,63 M -355.966,0 1,09 M 751.571,0
EPS (Diluted) -0,09 — — — —
Gross Profit 1,29 M 1,33 M 1,26 M 1,72 M 2,19 M
Operating Income -1,57 M -2,59 M -291.177,0 1,27 M 1,06 M
EBITDA — — — — —
R&D Expenses 47.511,0 — — — —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 13.929,0 — — —
Income Tax -3.494,0 -21.526,0 -52.310,0 — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2021
Total Assets 10,43 M 11,40 M 8,74 M 10,12 M 9,57 M
Total Liabilities 2,11 M 1,74 M 2,08 M 3,45 M 2,39 M
Shareholders' Equity 8,32 M 9,66 M 6,67 M 6,66 M 7,18 M
Total Debt — — — — —
Cash & Equivalents — — — 2,79 M 2,12 M
Current Assets 7,43 M 8,05 M 6,02 M 7,99 M 7,15 M
Current Liabilities 1,95 M 1,63 M 2,00 M 3,37 M 2,33 M